Celsion Corp. Company Profile (NASDAQ:CLSN)

Analyst Ratings

Consensus Ratings for Celsion Corp. (NASDAQ:CLSN) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.67 (285.67% upside)

Analysts' Ratings History for Celsion Corp. (NASDAQ:CLSN)
Show:
DateFirmActionRatingPrice TargetActions
7/22/2016Maxim GroupReiterated RatingBuy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016HC WainwrightReiterated RatingBuy$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/24/2015Cantor FitzgeraldReiterated RatingNot Available -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2015BTIG ResearchInitiated CoverageBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2015Griffin SecuritiesSet Price TargetBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2014Canaccord GenuityInitiated CoverageBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Celsion Corp. (NASDAQ:CLSN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/16/2016Q116($0.21)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q415($0.24)($0.24)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.26)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.31)($0.27)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q1($0.33)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015($0.36)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014($0.30)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.32)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.24)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014($0.28)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.23)($0.30)$0.13 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.07)$0.01$0.13 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.16)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2012Q312($0.17)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celsion Corp. (NASDAQ:CLSN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celsion Corp. (NASDAQ:CLSN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celsion Corp. (NASDAQ:CLSN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/17/2016Alberto R Martinez JrDirectorBuy5,000$1.35$6,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2016Michael H TardugnoCEOBuy7,500$1.35$10,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2016Michael H TardugnoCEOBuy3,000$1.27$3,810.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2016Michael H TardugnoCEOBuy2,000$1.27$2,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Alberto R Martinez JrDirectorBuy5,000$1.16$5,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016Michael H TardugnoCEOBuy4,500$1.20$5,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2016Michael H TardugnoCEOBuy6,500$1.13$7,345.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell5,556$2.08$11,556.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.15$43,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.11$21,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.19$21,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.23$44,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2015Alberto R Martinez JrDirectorBuy5,000$2.50$12,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Frederick J FritzDirectorBuy4,000$2.34$9,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Robert W HooperDirectorBuy4,000$2.50$10,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Alberto R Martinez JrDirectorBuy5,000$3.12$15,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Michael H TardugnoCEOBuy4,000$3.12$12,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Frederick J FritzDirectorBuy4,000$3.20$12,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014Alberto R Martinez JrDirectorBuy5,000$3.36$16,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2014Michael H TardugnoCEOBuy5,000$3.20$16,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Frederick FritzDirectorBuy2,500$3.86$9,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Michael TardugnoCEOBuy4,000$3.84$15,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Michael TardugnoCEOBuy2,800$3.59$10,052.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Frederick FritzDirectorBuy3,000$3.80$11,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Frederick FritzDirectorBuy10,000$1.09$10,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Michael TardugnoCEOBuy5,000$1.08$5,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Michael H TardugnoCEOBuy10,000$1.35$13,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Alberto R Martinez JrDirectorBuy5,000$0.93$4,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Alberto R Martinez JrDirectorBuy5,000$0.96$4,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Alberto R Martinez JrDirectorBuy5,000$0.92$4,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2013Alberto R Martinez JrDirectorBuy3,750$1.06$3,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2012Max LinkDirectorBuy14,000$7.60$106,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Robert W HooperDirectorBuy11,600$5.20$60,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Michael H TardugnoCEOBuy5,000$5.03$25,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2012Robert W HooperDirectorBuy10,000$4.95$49,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/29/2012Robert W HooperDirectorBuy2,500$4.65$11,625.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celsion Corp. (NASDAQ:CLSN)
DateHeadline
07/22/16 10:46 AMEarnings Focus and Crowd Sourced Sentiment Review for Celsion Corporation (NASDAQ:CLSN) - TGP
07/21/16 08:48 PMInsiders Increasing Positions in: Celsion Corp. (NASDAQ:CLSN) - Press Telegraph
07/20/16 04:24 PMCelsion Corporation (NASDAQ:CLSN) Shorts Decreased by 39.49% After Short Covering - Consumer Eagle
07/20/16 04:24 PMBroker Outlook For Celsion Corporation (CLSN) - Fiscal Standard
07/20/16 11:16 AMETF’s with exposure to Celsion Corp. : July 20, 2016 -
07/19/16 03:21 PMEquity Roundup: Stock Performance Focus on Celsion Corporation (NASDAQ:CLSN) - Press Telegraph
07/19/16 03:21 PMCelsion Corp. Realized Volatility Hits a Dropping Level - CML News
07/18/16 03:29 PMNext Weeks Broker Price Targets For Celsion Corporation (CLSN) - Fiscal Standard
07/17/16 03:04 PMShares Moving Down on the Week: Celsion Corp. (NASDAQ:CLSN) - Engelwood Daily
07/16/16 05:59 AMCrowd Rating and Earnings Recap for Celsion Corporation (NASDAQ:CLSN) - Telanagana Press
07/13/16 08:39 PMCelsion Corporation (NASDAQ:CLSN) Shorted Shares Increased 25.22% After Market Selling - Consumer Eagle
07/13/16 11:21 AMH.C. Wainwright Assumes Celsion Corp (CLSN) at Buy - StreetInsider.com
07/12/16 08:42 PMPhase III OPTIMA study highlighted at Asia-Pacific Primary Liver Cancer Expert meeting
07/12/16 08:42 PMMaxim Group Remains Bullish on Celsion (CLSN) Following Announced Phase lll OPTIMA Study
07/12/16 07:32 AMMaxim Group Remains Bullish on Celsion (CLSN) Following Announced Phase lll OPTIMA Study - StreetInsider.com
07/12/16 07:32 AMTrading Performance and Target Watch for Celsion Corporation (NASDAQ:CLSN) - Press Telegraph
07/12/16 07:32 AMCelsion Corporation (CLSN) Broker Price Targets For The Coming Week - Fiscal Standard
07/11/16 07:23 AMCelsion Announces Presentation Highlighting Phase III OPTIMA Study at the Asia-Pacific Primary Liver Cancer Expert Meeting - [at noodls] - July 11, 2016 LAWRENCEVILLE, N.J., July 11, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that its ongoing Phase III OPTIMA trial evaluating ThermoDox® in primary liver cancer, ...
07/07/16 07:21 AMCelsion Corporation to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - July 7, 2016 LAWRENCEVILLE, N.J., July 07, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that Michael H. Tardugno, chairman, president and chief executive officer, will present ...
07/07/16 07:00 AMCelsion Corporation to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [GlobeNewswire] - LAWRENCEVILLE, N.J., July 07, 2016-- Celsion Corporation today announced that Michael H. Tardugno, chairman, president and chief executive officer, will present at Cantor Fitzgerald’ s 2nd Annual Healthcare ...
07/06/16 09:03 PMIncreased Volatility Watch for: Celsion Corp. (NASDAQ:CLSN) - Engelwood Daily
07/06/16 09:03 PMBrokers Issue Average Price Target Of 8.20 On Celsion Corporation (CLSN) - Fiscal Standard
07/06/16 08:03 AMCelsion Corporation (NASDAQ:CLSN) Shorted Shares Increased By 25.22% - Press Telegraph
07/06/16 08:03 AMStock Rating Watch and Earnings Insight for Celsion Corporation (NASDAQ:CLSN) - Press Telegraph
07/01/16 08:24 PMRecently Issued Stock Ratings For Celsion Corporation (CLSN) - Fiscal Standard
06/23/16 10:13 AMNew Broker Ratings For Celsion Corporation (CLSN) - FTSE News
06/22/16 08:32 PMCelsion highlights potentially curative approach to treatment of primary liver cancer - DOTmed.com
06/22/16 08:32 PMCelsion Corporation (CLSN) Current Analyst Ratings - Fiscal Standard
06/22/16 07:59 AMCelsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer - The Focus of Hepatic ... - Nasdaq
06/21/16 07:39 AMCelsion Announces the Potentially Curative Approach to Treatment of Primary Liver Cancer - The Focus of Hepatic Oncology Peer-Reviewed Article - [at noodls] - June 21, 2016 Ongoing Phase III Trial to Confirm Hypothesis That The Combination of Standardized Radio Frequency Ablation (sRFA) Plus Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) May Substantially ...
06/19/16 03:05 PMCan Celsion Corporation (NASDAQ:CLSN) Surprise Analysts this Quarter? - Investor Newswire
06/18/16 07:53 AMA Director at Celsion Corp. (NASDAQ: CLSN) is Buying Shares - Analyst Ratings
06/17/16 04:01 PMCELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, -
06/15/16 03:54 PMCELSION CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matte -
06/13/16 02:43 PMCelsion (CLSN) Reports $6M Registered Direct Offering of Common Stock, Pre-funded Warrants - StreetInsider.com
06/13/16 01:09 PMCelsion Corporation Announces $6 Million Registered Direct Offering - [at noodls] - June 13, 2016 LAWRENCEVILLE, N.J., June 13, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (the 'Company') (NASDAQ:CLSN) today announced that it has entered into a definitive agreement with a single healthcare ...
06/13/16 01:06 PMCELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/07/16 10:08 AMCelsion Corp. :CLSN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 7, 2016 -
06/06/16 06:44 AMCelsion Corporation (NASDAQ:CLSN) Sellers Increased By 6.67% Their Shorts - HNN
06/01/16 04:10 PMCELSION CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits -
06/01/16 11:54 AMBuy, Sell Or Hold Rating For Celsion Corporation (CLSN)? - Share Trading News - Buy, Sell Or Hold Rating For Celsion Corporation (CLSN)?Share Trading NewsCelsion Corporation has a 50 day moving average of 1.51 and a 200 day moving average of 1.55. The stock's market capitalization is 31.64M, it has a 52-week low of 1.04 and a 52-week high of 2.72. The share price of the company (CLSN) was down -4.26%, ...SunOpta (NASDAQ:STKL) surged 26.70%: Celsion Corp. (NASDAQ:CLSN), ULTA Salon, Cosmetics & Fragrance ...Benchmark Monitorall 2 news articles »
05/31/16 09:00 PMStock Review and Earnings Check on Celsion Corporation (NASDAQ:CLSN) - HNN - Stock Review and Earnings Check on Celsion Corporation (NASDAQ:CLSN)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Celsion Corporation (NASDAQ:CLSN) to report quarterly EPS of $-0.23. The company's next earnings report is expected to be published on or ...and more »
05/31/16 10:37 AMJupai Holdings Limited (NYSE:JP) increased 3.09%: Nabors Industries Ltd. (NYSE:NBR), Celsion Corp. (NASDAQ ... - KC Register - Jupai Holdings Limited (NYSE:JP) increased 3.09%: Nabors Industries Ltd. (NYSE:NBR), Celsion Corp. (NASDAQ ...KC RegisterCompany has 1.20% insider ownership. Nabors Industries Ltd. (NYSE:NBR) quarterly performance is 27.57% while its year to date (YTD) performance is 7.33%. On 16 May, Celsion Corp. (NASDAQ:CLSN) reported a net loss of $5.7 million, or $0.24 per share ...and more »
05/31/16 10:37 AMCelsion Corp. (NASDAQ:CLSN) fell -6.00%: Milestone Scientific Inc. (NYSEMKT:MLSS), The Coca-Cola Company ... - KC Register - Celsion Corp. (NASDAQ:CLSN) fell -6.00%: Milestone Scientific Inc. (NYSEMKT:MLSS), The Coca-Cola Company ...KC RegisterOn 24 May, Celsion Corp. (NASDAQ:CLSN) provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of ...
05/25/16 11:31 AMBiotech Forum Daily Digest: The Biotech Rally Continues, Relypsa Gets Some Traction, Exelixis Living Up To Its Promise - Seeking Alpha - Biotech Forum Daily Digest: The Biotech Rally Continues, Relypsa Gets Some Traction, Exelixis Living Up To Its PromiseSeeking AlphaThe French drug maker is proposing to change Medivation's board after the company rejected its $9.3 billion takeover offer and refuses to engage in negotiations. I think Medivation could easily go for north of $10 billion when all is said and done ...
05/24/16 12:04 PMCELSION CORP Financials -
05/24/16 12:03 PMCelsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting - PR Newswire (press release) - Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 MeetingPR Newswire (press release)LAWRENCEVILLE, N.J., May 24, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating clinical trial combining GEN-1, the ...Celsion Corporation (CLSN) Updated Broker RatingsRisers & FallersCelsion Corporation (NASDAQ:CLSN) Shorts Decreased by 0.59% After Short CoveringFranklin IndependentNext Weeks Broker Price Targets For Celsion Corporation (CLSN)Share Trading Newsall 6 news articles »
05/24/16 07:16 AMCelsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting - [at noodls] - LAWRENCEVILLE, N.J., May 24, 2016 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose escalating ...
05/23/16 01:40 PMStock Rating Review for Celsion Corporation (NASDAQ:CLSN) - Wall Street Hints and News - Stock Rating Review for Celsion Corporation (NASDAQ:CLSN)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Celsion Corporation (NASDAQ:CLSN). Covering analysts will ...and more »
05/22/16 01:04 PMNext Weeks Broker Price Targets For Celsion Corporation (CLSN) - Share Trading News - Next Weeks Broker Price Targets For Celsion Corporation (CLSN)Share Trading NewsCelsion Corporation has a 50 day moving average of 1.50 and a 200 day moving average of 1.57. The stock's market capitalization is 33.26M, it has a 52-week low of 1.04 and a 52-week high of 2.78. The share price of the company (CLSN) was down -1.05%, ...and more »

Social

About Celsion Corp.

Celsion Corp. logoCelsion Corporation (Celsion) is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and ribonucleic acid (RNA)- or deoxyribonucleic acid (DNA)-based therapies. Its lead program is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CLSN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.21
  • 50 Day Moving Average: $1.31
  • 200 Day Moving Average: $1.39
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $28.36M
  • Beta: 2.19
  • Current Year EPS Consensus Estimate: $-0.81 EPS
  • Next Year EPS Consensus Estimate: $-0.5 EPS
Additional Links:
Celsion Corp. (NASDAQ:CLSN) Chart for Saturday, July, 23, 2016